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CSMS: Combined symptoms and medication score
DC: Dendritic cell
ILC: Innate lymphoid cell
ILC1: Group 1 innate lymphoid cell
ILC2: Group 2 innate lymphoid cell
ILC3: Group 3 innate lymphoid cell
lin: Lineage
mDC: Myeloid dendritic cell
NK: Natural killer
pDC: Plasmacytoid dendritic cell
tSNE: T-distributed stochastic neighbor embedding
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1866 ELJASZEWICZ ET ALBackground: Despite the efficacy of allergen-specific
immunotherapy (AIT), the role of trained immunity and
tolerance in this process has not been elucidated.
Objective: Here, we have performed a comprehensive
longitudinal analysis of the systemic innate immune cell
repertoire during the course of AIT.
Methods: Patients with allergy received standard preseasonal
subcutaneous AIT with allergoids to birch and/or grass.
Healthy controls were monitored without any intervention.
Flow cytometry of innate lymphoid cell (ILC), natural killer
cell, monocyte cell, and dendritic cell (DC) subsets was
performed at baseline, 3 months (birch season), 6 months
(grass seasons), and 12 months after the therapy in patients
or at similar seasonal time points in controls. Additional
analyses were performed in the third-year birch and grass
season.
Results: We observed a durable decrease in group 2 ILCs and
an increase of group 1 ILCs after AIT, with dynamic changes in
their composition. We found that an expansion of
CD1271CD2511 clusters caused observed shifts in the
heterogeneity of group 1 ILCs. In addition, we observed
development of CD1271CD2511c-Kit1 group 3 ILC clusters.
Moreover, we found an increase in the number of intermediate
monocytes in parallel with a reduction in nonclassical
monocytes during the first year after AIT. Classical and
intermediate monocytes presented significant heterogeneity in
patients with allergy, but AIT reduced the HLA-DR11 clusters.
Finally, an increase in plasmacytoid DCs and CD1411 myeloid
DCs was observed in individuals with allergy, whereas the
number of CD1c1 myeloid DCs was reduced during the first
year of AIT.
Conclusion: AIT induces changes in the composition and
heterogeneity of circulating innate immune cells and brings
them to the level observed in healthy individuals. Monitoring of
ILCs, monocytes, and DCs during AIT might serve as a novel
biomarker strategy. (J Allergy Clin Immunol 2021;147:1865-
77.)
Key words: Allergen immunotherapy, innate immune cells, antigen-
presenting cells, monocytes, DCs, ILC, NK cells
Currently, allergen-specific immunotherapy (AIT) remains the
only available causative treatment for patients with allergic
diseases such as allergic rhinitis and allergic asthma. AIT is
based on long-term administration of allergen preparations; it
mediates suppression of humoral and cellular effectors. In fact,
the vast majority of available studies focus on the mechanisms
of adaptive immune responses, mostly T- and B-cell responses,
whereas innate immune mechanisms remain elusive.1 Innate im-
mune cells such as innate lymphoid cells (ILCs), cytotoxic ILCs
(natural killer [NK] cells), monocytes/macrophages, and den-
dritic cells (DCs) orchestrate adaptive immune responses through
indirect (soluble factor release) and direct (cell-to-cell interac-
tion) mechanisms.2,3 Moreover, functional reprogramming of
innate immune cells caused by their initial activation may lead
to a more intense (trained immunity) or less intense (trained toler-
ance) response toward the second challenge and is referred to as
innate immune memory.4-6 It is possible that innate memory may
represent one of the mechanisms of successful AITand should be
associated with systemic changes in the composition andphenotype of different cell subsets. Therefore, understanding the
role of various innate immune cells during the course of AITwill
help to fully elucidate complex mechanisms providing long-
lasting tolerance to allergens.
On the basis of specific patterns of cytokine production,
membrane markers, and transcription factor expression, ILCs
are classified into 3 functionally distinct subsets, namely, group 1
ILCs (ILC1s), group 2 ILCs (ILC2s), and group 3 ILCs (ILC3s) ,
which resemble TH1, TH2, and TH17 subsets, respectively.
7 In
addition, thanks to the current advances in single-cell sequencing,
even greater heterogeneity of tissue and peripheral blood ILCs has
been reported.8-10 ILCs play a crucial function in the early stage
of antimicrobial response, tissue repair, and preservation of
epithelial integrity.11-14 ILC2s have essential functions in allergic
diseases. Increased numbers of these cells are observed in periph-
eral blood after allergen challenge, and they are regulated during
AIT.15-19 Thus, the role of ILCs in allergic inflammation, as well
as their phenotypical and functional heterogeneity, need further
evaluation.
Similar to ILCs, NK cells possess some functional similarities
with T cells and may regulate functions of other immune cells.
Two distinct subsets of circulating NK cells can be distinguished
on the basis of their expression of surface markers, namely,
CD561CD1611 and CD5611CD161/low NK cells. Notably,
CD561 NK cells represent the predominant subset (<_90%) on
the periphery; they act mainly as cytotoxic cells and produce
low levels of cytokines, whereas CD5611 NK cells are recog-
nized as cytokine producers.20 Interestingly, NK cells were re-
ported to be activated by allergen extracts in a nonspecific
manner, and they can promote a type 2 immune response and
eosinophilic inflammation.21
Monocytes and DCs are antigen-presenting cells, and they link
innate and adaptive immune responses. Notably, both subsetsmay
act as activators or regulators of immune responses depending on
their antigen-presenting capacities, associated with the expres-
sion of checkpoint molecules and cytokine profiles.22-24 In fact,
they have been proposed as crucial mediators of immunologic
tolerance,25-27 also in response to allergens in allergic rhinitis28
and in fatal asthma in children.29
Monocytes represent a heterogeneous cell population in terms
of phenotype and biologic properties. According to the differ-
ences in CD14 (LPS receptor) and CD16 (Fcg receptor III)
expression, 3 functionally distinct subsets exist in humans,
namely, classical (CD1411CD16–), intermediate
(CD1411CD161), and nonclassical (CD141CD1611)
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matory cells that subsequent to stimulation, release high amounts
of proinflammatory cytokines, including TNF, and they possess
high cytotoxic and phagocytic activities. Elevated frequencies
of these cells are observed in proinflammatory diseases, infec-
tions, and sepsis.30 In contrast, intermediate monocytes have
been referred to as anti-inflammatory because following stimula-
tion, they constitute the principal source of IL-10 among all 3 sub-
sets31,32; they also play essential roles in vascularization, tissue
repair, and regeneration processes, as well as in induction of toler-
ance.26,33,34 Notably, it is well established that monocytes may
serve as macrophage and DC progenitors. In fact, both CD161
subsets are referred to as activated monocytes and are considered
a more mature form of monocytes when compared with the clas-
sical subset, which can subsequently differentiate into monocyte-
derived DCs.31,35
It is generally accepted that 3 distinct DC subsets can be
distinguished in peripheral blood in humans, namely,
plasmacytoid DCs (pDCs), (CD3031 pDCs), CD1c1 myeloid
DCs (mDCs), and CD1411 mDCs, with an additional extent
of heterogeneity being discovered as a result of single-cell
sequencing.32,36 pDCs are considered an immature form of
DCs because after a contact with antigen, which acts as a
maturation signal, they can present antigen to the T cells
immediately in the lymph nodes. The remaining 2 subsets of
mDCs show features of both immature DCs and CD3031 DC
precursors.32 Interestingly, it has been previously postulated
that mDCs are involved mainly in the development of TH2 re-
sponses, whereas pDCs may induce antiviral responses or
orchestrate tolerance development by induction of regulatory
T cells.37-39
In this study, we analyzed dynamic changes in the systemic
innate immune responses at several time points during the course
of preseasonal subcutaneous allergen-specific immune therapy
for birch and grass pollens and compared them with the
physiologic responses in healthy controls.METHODS
Patients and healthy controls
Subjects allergic to grass and/or birch pollen and healthy allergy-free
nonatopic controls were recruited in spring and summer 2015 at Inselspital
Bern (Bern, Switzerland). The study was initiated from December 2015 to
January 2016, when patients received preseasonal subcutaneous immuno-
therapy to birch and/or grass. All subjects lived in the Bern region. The
patients were clinically diagnosed with pollen allergic rhinitis (symptoms in
birch and/or grass season on the basis of positive skin prick test results and
the presence of allergen-specific IgE, as assessed with Immunocap (Phadia
AB, Uppsala, Sweden). Some patients had concomitant well-controlled
allergic asthma.40 The patients did not have any other clinically significant
concomitant acute or chronic diseases. Further exclusion criteria were preg-
nancy, noncompliance, inability to follow the study procedures, drug or
alcohol abuse, or participation in a study involving investigational drug
use 1 month before and during the course of this study. A total of 12
nonatopic, allergy-free healthy control subjects from the same region as
the patients with allergy were followed at the same seasonal time points as
the patient population to control for potential seasonal changes in the innate
immune cell populations. Detailed demographic and clinical characteristics
of the study participants are shown in Table I. This study has been reviewed
and approved by the ethics committee of the Canton of Bern (Switzerland).
Each participant was familiarized with the objectives of the study and pro-
vided written consent.Preseasonal birch and/or grass pollen
immunotherapy, study design, and sampling
All of the patients with allergy started the first course of subcutaneous
preseasonal AIT at some point between the end of November 2015 and the
beginning of January 2016, and again in the same format in the following 2
years (see Fig E1,A in this article’s Online Repository at www.jacionline.org).
According to their diagnosis, patients received subcutaneous injections of
depot allergen extracts of grass and/or tree pollen preparations containing
the adjuvant alum (Allergopharma Merck, Reinbek, Germany) (see Fig E1,
B and C). The standard therapy protocol consisted of increasing concentra-
tions in a total of 7 to 9 injections (see Fig E1, B and C) given within first 2
to 3 months. For patients receiving both tree and grass pollen AIT, the prepa-
rations were injected separately, each into opposite arms. Birch and grass pol-
len counts were retrieved from the Federal Office of Meteorology and
Climatology MeteoSwiss (Zurich-Airport, Switzerland) (see Fig E1, D and
E). Blood samples were collected at 4 time points—time point 0 (immediately
before the start of preseasonal AIT), after 3 months (at the end of preseasonal
therapy [at the peak of birch pollen season]), after 6 months (at the peak of
grass pollen season), and at 12 months (out of season) for patients—and at
similar time points for the healthy controls (see Fig E1).41 In the follow-up,
we also collected blood samples from a small subset of patients at 27 and
30 months after the start of AIT.
Venous blood samples were collected at Inselspital Bern and transported to
the Swiss Institute for Allergy and Asthma Research (Davos, Switzerland) at
ambient air temperature within 6 hours after venipuncture. The blood was
further processed for direct whole blood sample staining with flow cytometry
antibodies, plasma collection, PBMC isolation, and subsequent flow cytom-
etry with different panels.
Clinical response to AITwas assessed according to the European Academy
of Allergy and Clinical Immunology (EAACI) guidelines.42 Combined
symptom and medication scores (CSMSs) were recorded by the CSMS
questionnaires in the doctor’s office in the season before, and at each study
visit, together with sampling. Nonresponders to AIT were defined as those
subjects who had 30% or less improvement in their CSMS as compared
with during the season preceding initiation of AIT. Total levels of IgE, IgE
specific to Phleum pratense 1 combined with Phleum pratense 5b, and IgE
specific to Betula verrucosa 1 antibodies were measured in plasma by using
Immunocap.
Flow cytometry
For ILCs analysis, 20 million freshly isolated PBMCs were stained with a
panel of anti-human antibodies. All antibodies with their clones and
manufacturers are presented in Table E1 (in this article’s Online Repository
at www.jacionline.org). ILCs were characterized as viable, lineage-negative
(lin–) (CD3–CD4–CD19–CD14–CD16–CD1a–CD11c–CD34–CD94–CD123–
CD303–FcεRIa–) CD1271 cells and further discriminated as CRTH21ILC2,
CRTH2–c-Kit– ILC1, or CRTH2–c-Kit1NKp44– ILC3 (applied gating strat-
egy is presented in Fig E2 (in this article’s Online Repository at www.
jacionline.org).
For immunophenotyping of monocytes, DCs, and NK cells, 200 mL of fresh
whole blood was stainedwith a panel of anti-human antibodies according to the
stain-lyse-wash protocol. Briefly, antibodies were added to 200 mL of whole
blood samples, mixed, and incubated for 30 minutes at room temperature in the
dark. Next, 2 mL of lysing buffer (Becton Dickinson) was added for red blood
cell lysis. Finally, the samples were washed in phosphate-buffered saline (PBS)
and analyzed byusing flow cytometry.Monocyteswere classified on the basis of
morphology and fluorescent markers (viable CD3–CD19–CD141). Subpopula-
tions were identified as classical, intermediate, and nonclassical monocytes by
their expression of CD1411CD16–, CD1411CD161, or CD141CD1611,
respectively (see the applied gating strategy in Fig E3 in this article’s Online Re-
pository at www.jacionline.org). DC subsets were classified as viable
CD3–CD19–HLA-DR1 cells and on the basis of expression of specific markers,
namely, CD12311CD3031 for pDCs, HLA-DR11CD1c1 for CD1c1 mDCs,
and CD14–CD14111 for CD1411 mDCs (see the applied gating strategy in
Fig E4 in this article’s Online Repository at www.jacionline.org). NK cells
were classified as viable CD19–CD4–CD14–CD561/11CD161/11 cells (see
TABLE I. Demographic and clinical characteristics of the study participants
Characteristics Patients with allergy (n 5 13) Healthy controls (n 5 12) P value
Demographic characteristics
Age (y), median (range) 27 (19-36) 35.5 (23-63) .0222
Sex, female/male (no./no.) 5/7 10/2 .0894
Weight (kg), median (range) 77 (63-100) 66.5 (53-102) .0612
Height (cm), median (range) 172 (162-187) 169 (153-188) .2295
Clinical data
Allergic rhinitis (yes/no) 13/0 0/12 <.0001
Asthma (yes/no) 8/5 0/12 .0016
Positive SPT result (yes/no) 13/0 0/12 <.0001
Total IgE level (kU/L), median (range) 106 (28-274) 26 (10-73) .0003
Phl p 1 1 Phl p 5 IgE level (kU/L), median (range) 9.88 (1.59-68.9) nd <.0001
Bet v 1 IgE level (kU/L), median (range) 2.99 (0.1-36.4) nd .0005
FEV1 (% predicted), median (range) 101 (79-122) n/a n/a
Allergen immunotherapy
Birch (yes/no) 10/3 n/a n/a
Grass (yes/no) 12/1 n/a n/a
Clinical nonresponders to birch AIT, no. (%)* 2 (15.4) n/a n/a
Clinical nonresponders to grass AIT, no. (%)* 3 (23.1) n/a n/a
Bet v, Betula verrucosa; n/a, not applicable; nd, not determined; Phl p, Phleum pratense; SPT, skin prick test.
Data were analyzed by using the Mann-Whitney and Fisher exact test, as appropriate.
*Nonresponders to AIT were assessed as having a 30% or lower decrease in CSMS, as compared with the level during the appropriate pollen season preceding initiation of AIT.
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All specimens were acquired by using a FACS ARIA III flow cytometer
followed by data analysis in FlowJo 10.1 software (TreeStar, Ashland, Ore).
Classical gating and t-distributed stochastic neighbor embedding (tSNE)
algorithms were used to assess the subpopulations. The frequency of each
analyzed subpopulation was calculated in the parent population in gating,
unless otherwise specified. Total cell number was recalculated per microliter
of whole blood, on the basis of the initial values measured by using a Sysmex
cell counter.
For 2-dimensional reduction of manual gates FlowJo tSNE plugin software
was used. The data from each time point of each individual patient were evenly
downsampled to ensure that tSNE analysis would be performed at the same
number of events, namely, the highest event number in the particular gate
available in all time points. Next, all files were concatenated into a new data
file and the tSNE algorithm was applied. The following settings were used for
the tSNE algorithm: perplexity, 20 (P_20); learning rate, 200 (E_200);
iterations, 600 (I_600); and theta, 0.5 (T_0.5).Statistics
Statistical analysis was conducted by using GraphPad Prism 7 software
(GraphPad Software, La Jolla, Calif). Categoric variables were analyzed with
the Fisher exact test, whereas continuous variables were analyzed with the
Mann-WhitneyU test, as appropriate. TheWilcoxon test was used to compare
changes between different time points. The differences were considered statis-
tically significant at a P value less than .05.RESULTS
ILC2s and ILC3s decrease during the course of AIT
First, we investigated the effect of AIT on the frequency and
absolute numbers of the 3 main and best-characterized subsets
of ILCs, namely ILC1, ILC2, and ILC3 (Fig 1, A). Three types
of comparisons were made: (1) first-year time points were
compared with baseline, (2) third-year time points after initia-
tion of AIT were compared with the first-year time points;
and (3) patients with allergy were compared with the healthy
controls at the same time points. We found increasedfrequencies and numbers of ILC1s at the 6- and 12-month
time points (Fig 1, B and see Fig E6, A in this article’s Online
Repository at www.jacionline.org). In contrast, the frequency of
ILC2s was decreased after 12 months. Interestingly, the fre-
quency of ILC2s decreased most between the 6- and 12-
month time points; however, only a trend can be observed in
ILC2 numbers (Fig 1, C and see Fig E6, A in this article’s On-
line Repository at www.jacionline.org). ILC3 frequency also
decreased after 12 months (Fig 1, D).
Importantly, we noticed that the observed first-year effects
of AIT on ILC subsets remained stable or were even more
profound in the third year (see Fig E6, B). In particular, we
observed a further increase in the frequency of ILC1s and a
further decrease in the frequency of ILC2s. We found no changes
in the frequency of ILC3s between the first and third year of
AIT in the birch pollen season, whereas the frequency of ILC3s
in the grass pollen season was increased (at the 6- vs 30-month
time points).
Having found the time course changes in ILC subsets during
the first year after AIT, we evaluated the differences between the
frequency of the analyzed cells in individuals with allergy during
the course of AIT and that in the matched controls at the same
seasonal time points. The healthy controls showed no seasonal
changes in any of the analyzed ILC subsets (see Fig E6, C). In a
comparison of controls with patients at the same time points, a
lower frequency of ILC1s in patients with allergy at baseline
and 6 months after initial treatment was observed (Fig 1, E). After
12 months of treatment, there was no difference in the ILC1 fre-
quency between patients and controls. An elevated frequency of
ILC2s in the donors with allergy was demonstrated at baseline
and at 6 months (in the grass pollen season); however, they
became equally frequent in patients and controls after 12 months
(Fig 1, F). There were no differences in the frequency of ILC3s
between patients and controls at any of the analyzed seasonal
time points (Fig 1, G).
Next, we used the tSNE algorithm to analyze heterogeneity of







































































































































































FIG 1. AIT-induced decrease in ILC2s and ILC3s. A, Representative gating of ILC1s, ILC2s, and ILC3s among
lin–CD1271 ILCs. Summary of flow cytometry analyses of AIT-induced changes in the frequency of ILC1s (B),
ILC2s (C), and ILC3s (D) in patients with allergy during the course of AIT (n 5 11 [the Wilcoxon test was
used]). Each ILC subset is shown as a percentage in the lin–CD1271 gate. Comparison of seasonal changes
of ILC1s (E), ILC2s (F), and ILC3s (G) between allergy-free healthy controls (n5 12), and patients with allergy
(n5 11) during the course of AIT. The Wilcoxon test was used to compare differences between time points.
TheMann-WhitneyU test was used to compare differences between the controls and patients who received
AIT. *P < .05; **P < .01; ***P < .001.
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separately, confirming use of the correct gating strategy (see
tSNE ILC subsets in Fig E2). As a result of in-depth analysis of
cluster heterogeneity with subsequent quantification of the newly
identified subsets by classical gating, we noticed intriguing
changes in the ILC1 and ILC3 phenotypes, but not in the ILC2
phenotypes over time. Briefly, AIT induced an increase in the
numbers of ILC1 clusters with higher CD25 expression (Fig 2,
A), thus making their signature comparable to that of allergy-
free individuals at 12 months (see Fig E7 in this article’s OnlineRepository at www.jacionline.org). In fact, there was a significant
elevation of the frequency of the CD1271CD2511 cluster at the
6-month time point (Fig 2, B). In contrast, the frequency of
theCD12711CD2511 subset decreased at 12 months when
compared with baseline (Fig 2, C). Interestingly, we found that
ILC2s were quite heterogenous, but there were no significant
changes in the presence (Fig 2, D and see Fig E8 in this article’s
Online Repository at www.jacionline.org) or frequency of ILC2
clusters (Fig 2, E and F) over time. The signature of the ILC3 sub-
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FIG 2. AIT-induced changes in the heterogeneity of circulating ILCs. Representative tSNE 2-dimensional
plots showing changes in the complexity and clustering of different circulating ILC subsets at each analyzed
time point in patients with allergy who received AIT. A, ILC1 clustering and quantification of CD1271CD2511
ILC1 clusters (B) and CD12711CD2511 ILC1 clusters (C) (n 5 10). D, ILC2 clustering and quantification of
c-Kit1CD2511 ILC2 clusters (E) and c-Kit-CD2511 ILC2 clusters (F) (n 5 11). G, ILC3 clustering and quantifi-
cation of CD1271CD2511c-Kit1 (H) and CD12711CD2511c-Kit11 ILC3s (I) (n 5 11). For tSNE analysis, the
cells were gated as described in Fig E2 and a 2-dimensional reduction was performed from the lin–CD1271
gate (total ILCs) for NKp44, CRTH2, CD25, CD127, c-Kit, and ILT3 expression. The following settings were
applied for the tSNE algorithm: perplexity, 20 (P_20); learning rate, 200 (E_200); iterations, 1000 (I_1000);
and theta, 0.5 (T_0.5). Graph overlays were performed to visualize changes in cluster complexity of the
different ILC subsets, namely, ILC1s (A), ILC2s (D), and ILC3s (G). For novel subset quantification, manual
gating was applied. The Wilcoxon test was used to compare differences between time points. *P < .05;
**P < .01; ***P < .001.
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trols (see Fig E9 in this article’s Online Repository at www.
jacionline.org). At 3 months and at 6 months after initiation of
AIT, there was an increase in the complexity of the ILC3 clusters,
associated with the expansion of CD1271CD2511c-Kit1 (Fig 2,
H) and a decrease of CD12711CD2511c-Kit11 cells (Fig 2, I).
A detailed description of ILC clusters can be found in the
Results section of the Online Repository (at www.jacionline.
org) and also in Figs E7 and E9.
Taken together, our data suggest that AIT limits the
numbers of circulating ILC2s and ILC3s in favor of an
expansion of the number of ILC1s. In addition, AIT also
induces an increase in ILC1 and ILC3 heterogeneity, bringing
their phenotypes closer to that of the healthy controls. This
may reflect trained tolerance to reduce seasonal induced
allergic inflammation.AIT does not affect the composition of circulating
NK cells
Having found AIT-induced changes in the composition of
ILCs, we next analyzed changes in the frequency and numbers of
ILCs with cytotoxic potential, namely, CD561CD1611 (CD56
dim) and CD5611CD161/– (CD56 bright) NK cells (Fig 3, A).
We observed no changes in the frequency of NK cells in patients
with allergy who were undergoing AIT, mainly owing to huge in-
dividual variations (Fig 3, B and C). Similarly, we found no sig-
nificant changes in the numbers of both analyzed subsets
(see Fig E10, A in this article’s Online Repository at www.
jacionline.org). As an interesting finding that requires further
investigation, allergy-free individuals showed a significant
decrease in the frequencies of both CD56 bright and CD56 dim
NK cells during the birch season (3 months [see Fig E10 in this












































































































































FIG 3. AIT does not affect the composition of circulating NK cells. A, Representative gating for
CD5611CD161/– and CD561CD1611 NK cells. Summary of flow cytometry analyses of AIT-induced changes
in the frequency of CD561CD1611 NK (B) and CD5611CD161/– (C) cells in patients with allergy during the
course of AIT (n 5 11). Comparison of seasonal changes of CD5611CD1611 (D) and CD561CD161/– (E) NK
cells between allergy-free healthy controls (n 5 12), and patients with allergy during the course of AIT
(n 5 11). The Wilcoxon test was used to compare differences between time points, and the Mann-
WhitneyU test was used to compare differences between controls and patients who received AIT. **P < .01.
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NK cells in patients with allergy at the 3-month time point, as
compared with healthy controls, whereas no differences were
observed at 6 and 12 months (Fig 3, D). Moreover, no differences
in the frequency of CD5611CD161/– NK cells were observed be-
tween patients receiving AITand healthy controls at the same sea-
sonal time points (Fig 3, E).
In summary, AIT did not change the systemic distribution of
cytotoxic ILCs. It seems, therefore, that circulating NK cells may
play a minor role in the AIT-reinduced tolerance to allergens.Monocytes shift from proinflammatory toward anti-
inflammatory phenotypes during the course of AIT
Next, we aimed to assess the composition of circulating innate
immune cells with antigen-presenting capacities. First, we
analyzed the composition and heterogeneity of peripheral blood
monocytes (Fig 4, A). We observed a substantial decrease in the
frequency of nonclassical CD141CD1611 monocytes already
at 3 months (Fig 4, B). This decrease was even more profound
at 6 months (Fig 4, B and see Fig E11, A in this article’s Online
Repository at www.jacionline.org). Moreover, there was a steady
increase in the frequency of intermediate CD1411CD161mono-
cytes during the course of AIT, reaching a maximum at 12months
(Fig 4, C and see Fig E11, A), whereas the frequency of classical
CD1411CD16– monocytes showed alterations reflecting changes
in the other subpopulations (Fig 4, D and see Fig E11, A in this
article’s Online Repository at www.jacionline.org).
Notably, in contrast to the effects of AITon the ILC subsets, the
effects of AIT on the composition of different monocyte subsetswas less stable over time (see Fig E11, B in this article’s Online
Repository at www.jacionline.org). In contrast to the early
(first-year) effects of AIT, we found a significant increase in the
frequency of CD141CD1611 nonclassical monocytes in the
third-year pollen season. Simultaneously, the frequency of
CD1411CD161 intermediate monocytes did not increase at
that time (see Fig E11, B).
Next, we compared the frequency of different monocyte
subsets between patients with allergy and healthy controls at
the same time points. Interestingly, we found that there was a
slightly reduced frequency of nonclassical monocytes at 12
months in patients (Fig 4, E). Surprisingly, no differences were
observed in intermediate monocytes (Fig 4, F). However, we
noticed slight, but significant differences in classical monocytes
at 3 and 6 months (Fig 4, G and see Fig E11, C).
tSNE analysis of the different monocyte subsets demonstrated
that all of the analyzed clusters separated from other cell types,
confirming their distinct phenotype (see the tSNE APC subsets in
Fig E3). We found no change in the complexity of nonclassical
monocytes in the patients receiving AIT (Fig 5, A) and healthy
controls (see Fig E12 in this article’s Online Repository at
www.jacionline.org), yet there was an increase in the expression
of HLA-DR (Fig 5, B), with stable expression of CD141 in this
subset (Fig 5,C). In contrast, we noticed significant heterogeneity
in the remaining 2 subsets, namely, intermediate and classical
monocytes. Briefly, we observed a reduction of HLA-DR11 clus-
ters in the intermediate monocytes (Fig 5, D and see Fig E13 in
this article’s Online Repository at www.jacionline.org), and we
further confirmed it by quantification of HLA-DR (Fig 5, E)


























































































































































































































































FIG 4. Monocyte shift from proinflammatory toward anti-inflammatory phenotypes during the course of
AIT. A, Representative gating for CD1411CD16– classical, CD1411CD161 intermediate, and CD141CD1611
nonclassical monocytes and representative dot plots of different monocyte subsets at each analyzed time
point. Summary of flow cytometry analyses of AIT-induced changes in the frequency of CD141CD1611
nonclassical (B), CD1411CD161 intermediate (C), and CD1411CD16– classical monocyte (D) subsets in pa-
tients with allergy who were receiving AIT (n 5 12). Comparison of seasonal changes of CD141CD1611
nonclassical (E), CD1411CD161 intermediate (F), and CD1411CD16– classical (G) monocyte subsets be-
tween allergy-free healthy controls (n 5 12), and patients with allergy (n 5 12) during the course of AIT.
The Wilcoxon test was used to compare differences between time points. The Mann-Whitney U test was
used to compare differences between controls and patients receiving AIT. *P < .05; **P < .01; ***P <
.001. ns, Not significant.
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in patients with allergy (Fig 5, G and see Fig E14 in this article’s
Online Repository at www.jacionline.org). Consequently, there
was a slight decrease in HLA-DR expression from 3 months to
12 months (Fig 5,H) and a significant decrease of CD141 expres-
sion from 6 months to 12 months (Fig 5, I). A more detailed
description of the different monocyte clusters can be found
in the Results section of the Online Repository and in Figs E12
to E14.
In summary, we found that AIT reduced the number of
nonclassical monocytes with no changes in their composition.
Moreover, we observed an increase in the number of inter-
mediate monocytes in patients during AIT, accompanied by
the dynamic changes in the composition of these cells that
were associated with the expansion of clusters with lower
HLA-DR expression. The observed reduction in HLA-DRexpression on intermediate monocytes, together with the
increase in the frequency of these cells, complementary
with the decrease in nonclassical, proinflammatory mono-
cytes, may reflect a shift toward anti-inflammatory/tolerogenic
phenotypes. It indicates a trained, systemic response to limit
local inflammation.CD1c1 mDCs, but not CD1411 mDCs and pDCs, are
downregulated during the course of AIT
Next, we aimed to analyze whether AIT induces changes in the
phenotype and composition of peripheral blood DC subsets,
namely CD1c1 mDCs, CD1411 mDCs, and pDCs. In contrast to
the different monocyte subsets showing varying expression levels
of CD14 and CD16, peripheral blood DCs have been character-
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FIG 5. AIT-induced changes in the heterogeneity of different subsets of monocytes. Representative tSNE 2-
dimensional plots representing changes in complexity and clustering of different monocytes subsets at
each analyzed time point. For tSNE analysis, the cells were gated as follows. First, flow check control was
applied to gate out all disruptions in the instrument performance. Next, doublet discrimination was
performed according to both forward scatter (FSC-H and FSC-A) and side scatter (SSC-H vs SSC-W),
followed by dead, CD3, and CD19 cell discrimination (viability). Next HLA-DR1 cells were gated. Finally, 2-
dimensional reduction was performed from HLA-DR1 cells for CD1c, CD14, HLA-DR, CD16, CD123, CD141,
and CD303 expression. The following settings were applied for the tSNE algorithm: perplexity, 20 (P_20);
learning rate, 200 (E_200); iterations, (I_600); and theta, 0.5 (T_0.5). Graph overlays were performed to visu-
alize changes in cluster complexity: A, CD141CD1611 nonclassical monocytes clusters with quantification
of HLA-DR (B) and CD141 MFI (C). D, CD1411CD161 intermediate monocyte clusters with quantification
of HLA-DR and CD141 expression (E). G, CD1411CD16– classical monocyte clusters and quantification of
HLA-DR (H) and CD141 (I) MFI (n 5 11). The Wilcoxon test was used to compare differences between
time points. *P < .05; **P < .01; *** P < .001.
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increase in the frequency of pDCs at the 6- and 12-month time
points comparedwith at 3months (Fig 6,B). In addition, we found
a substantial decrease in the frequency and numbers of CD1c1
mDCs during the course of AIT when compared with baseline
(Fig 6, C and see Fig E15, A in this article’s Online Repository
at www.jacionline.org). Similarly to nonclassical monocytes,
CD1c1 mDCs decreased significantly after 3 months of AIT
and even further after 6 months (Fig 6, C). In addition, we
observed a slight elevation of the frequency of CD1411 mDCs
at 12 months compared with at 3 months (Fig 6, D). However,
no differences were observed in the numbers of CD1411
mDCs, mainly owing to noticeable individual variations (seeFig E15, A in this article’s Online Repository at www.
jacionline.org).
Similarly to monocytes, the AIT-induced changes in the
composition of DCs in the pollen season of the first year seemed
to be modified in the subsequent seasons. We found a lower
frequency of pDCs in the third-year birch pollen season compared
with at 3 months after AIT (see Fig E15, B). The frequency of
CD1c1 mDCs in the third-year birch and grass pollen seasons re-
mained comparable to the levels observed in the first year after
AIT. In contrast, the frequency of CD1411 mDCs decreased
significantly in the third-year birch pollen season and was slightly
increased in the grass pollen season, but it still remained lower
than in the representative seasons of the first year.
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FIG 6. pDCs and CD1411 mDCs are upregulated, whereas CD1c1 mDCs are downregulated during the
course of AIT. A, Representative gating for pDCs, CD1c1 mDCs, and CD1411 mDCs. Summary of flow cy-
tometry analyses of AIT-induced changes in the frequency of CD12311CD3031 pDCs (B), HLA-DR11CD1c1
mDCs (CD1c1 mDCs) (C), and CD14–CD14111 (CD1411 mDCs) (D) in patients with allergy during the course
of AIT (n5 12). Representative tSNE 2-dimensional plots representing changes in complexity and clustering
of different DC subsets at each analyzed time point in individuals with allergy (E) and healthy allergy-free
individuals (F). For tSNE analysis, the cells were gated as follows. First, flow check control was applied to
gate out all disruptions in the instrument performance. Next, doublet discrimination was performed accord-
ing to both forward scatter (FSC-H and FSC-A) and side scatter (SSC-H vs SSC-W), followed by dead, CD3,
and CD19 cell discrimination (viability). Next, HLA-DR1 cells were gated. Finally, 2-dimensional reduction
was performed from HLA-DR1 cells for CD1c, CD14, HLA-DR, CD16, CD123, CD141, and CD303 expression.
The following settings were applied for the tSNE algorithm: perplexity, 20 (P_20); learning rate, 200 (E_200);
iterations, (I_600); and theta, 0.5 (T_0.5). The Wilcoxon test was used to compare differences between time
points. *P < .05; **P < .01; ***P < .001.
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controls and the differences between patients with allergy and
healthy controls at each analyzed time point (see Figs E15, C and
E16). We observed a higher frequency of pDCs in healthy con-
trols when compared with individuals with allergy at baseline,
whereas we saw the reverse picture at 12 months, which resulted
from an increase in pDCs in the patients and a decrease in the
healthy controls. The frequency of CD1c1 mDCs was lower in
the patients with allergy at the 3-, 6-, and 12-month time points
when compared with their frequency in allergy-free individuals.
The patients with allergy presented a significantly higher fre-
quency of CD1411 mDCs at 6 and 12 months after initiation of
AIT when compared with the frequency in allergy-free individ-
uals at the same time points.
tSNE analysis demonstrated that both in the patients with
allergy and in the controls, CD1c1 mDCs were phenotypically
heterogeneous at baseline (Fig 6, E and F and see Online Repos-
itory Fig E17 in this article’s Online Repository at www.
jacionline.org) and clustered into 3 separate populations. The
complexity of CD1c1 mDC clusters was associated with subtly
different expression of CD1c and HLA-DR (see Fig E17). How-
ever, during AIT the complexity of CD1c1 mDCs clusters
decreased (Fig 6, E), whereas in some of the healthy controls it
increased (Fig 6, F). In contrast, pDCs and CD1411 mDCs
formed only 1 cluster per subset at baseline and remained stable
during AIT. A detailed description of the tSNE analysis of the
DC clusters can be found in the Results section of the Online
Repository (see Fig E17).
Overall, we found that AIT induced a substantial increase in
pDCs, with no change in their composition. Moreover, we
observed a decrease in the frequency of CD1c1 mDCs during
AIT. Furthermore, we found a slight increase in CD1411 mDCs
in late time points of AIT. Finally, the heterogeneity of DCs as-
sessed by tSNE analysis seems to be less complex than that of
ILCs and monocytes. It all suggests that AIT-induced changes
in the distribution of DC subsets increases their regulatory
potential.43DISCUSSION
The mechanisms of immune tolerance to allergens have been
studied in humans by using various models, including AIT.
Recent advances in understanding of the mechanisms of trained
immunity in ILCs,5 monocytes/macrophages,44 and DCs,44,45 as
well as regulatory functions of ILCs or DCs,46,47 strongly suggest
that changes in these compartments should be studied in more
detail in regard to induction of immune tolerance. In the present
study, we demonstrated the results of 1 year of follow-up of circu-
lating innate immune cells at 4 time points during the preseasonal
AIT in comparison with the results for healthy controls at the
same time points. Moreover, we extended the follow-up and as-
sessed the composition of different innate immune subsets at
the third-year time points, analyzing the stability of observed al-
terations. We showed that subcutaneous AIT for aeroallergens
caused dynamic changes in the systemic innate immune response;
in particular, we showed changes associated with the increased
immunoregulatory phenotypes of innate immune cells. Thus,
the observed shifts may underlie mechanisms facilitating trained
tolerance to allergens.
Successful AIT is defined as a treatment that causes a
significant reduction in allergic symptoms and the need formedications, with a concomitant decrease in proinflammatory
cells and a subsequent increase in cell populations with anti-
inflammatory or regulatory properties. These phenomena were
often observed by our group and others in allergen-specific T-
cell and B-cell compartments.48-51 Notably, type 2 inflammation
is a hallmark of allergic disease and is regulated by TH2 effector
cells, releasing related cytokines (including IL-4, IL-5, IL-9, and
IL-13).52 In addition, a growing body of evidence shows that
ILCs, namely, ILC2s, support type 2 inflammation as an early
source of IL-5 and IL-13 in response to epithelial-derived
molecules, such as IL-33 and thymic stromal lymphopoietin.7,53
Therefore, ILC2s are considered to reflect effector TH2
cells in their cytokine expression pattern.53 More importantly,
allergen-trained (experienced) ILC2s were shown to persist
long after resolution of inflammation and respond to the repeated
allergen exposure more potently than untrained ‘‘naive’’ ILC2s
did. Thus, they mediate more severe and long-term memory-
like response to allergens.54 Although the effector functions of
ILC2s are associated with local inflammation, their rapid induc-
tion has been shown on the periphery after allergen challenge,55
suggesting their trained immunity. Therefore, it is possible that
circulating ILCs play an important role in regulation of allergic
inflammation.18 This explains the observed higher frequency of
circulating ILC2s in individuals with allergy at baseline and in
the pollen season that were reduced by AIT and finally reached
the levels observed in healthy controls. These changes may
result from the AIT-mediated trained tolerance, and they remain
stable up to third year after AIT.56,57 Our findings support previ-
ous reports showing significant decrease in ILC2s during the
course of subcutaneous AIT,17,19 with the novel findings about
the relative stability of their intrasubset clusters. ILC2s possess
phenotypic heterogeneity and functional plasticity,8-10,58 which
has not been previously studied in the context of AIT. Recently,
c-Kit1 ILC2s were shown to retain an ILC3-like phenotype and
the ability for the conversion to IL-17-producing ILC3s.59,60 On
the other hand, however, a c-Kit–/low subset has been proposed to
represent fully matured and lineage-committed ILC2 subset with
high expression of GATA3 and high secretion of type 2 cyto-
kines.60 In our study, the vast majority of ILC2s were c-Kit–;
however, we also detected a small ILC2 cluster with low c-Kit
expression in both allergic and allergy-free individuals. Interest-
ingly, the c-Kitlow cluster was not presented as a separate peak in
the grass pollen season in both allergic and allergy-free individ-
uals. It seems that AIT may not only reduce the frequency of
ILC2s but may also limit their heterogeneity during the pollen
season. However, our understanding of ILC2 plasticity in pa-
tients with allergy within the season needs to be further evalu-
ated. Similarly, to date, the role of circulating ILC1s and
ILC3s in allergic inflammation has remained elusive and needs
more attention. In this study, we found that the frequency and
heterogeneity of ILC1s and ILC3s changed after AIT. Within
the set of ILC1s, we found an expansion of a novel cluster of
CD2511 ILC1s. Furthermore, we observed the emergence of a
novel cluster of CD1271CD2511c-Kit1 ILC3s during therapy.
The appearance of CD2511 ILC1 clusters may indicate acquisi-
tion of a regulatory phenotype, as shown previously for ILC2s.47
NK cells do not seem to play a significant role in AIT because no
differences in the frequency of either CD5611CD161/– or
CD561CD1611 subsets were observed.
Until recently, only a limited number of studies in humans have
referred to the changes in the phenotype of antigen-presenting
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tolerogenic phenotype of DCs, which consequently may lead to
the induction of regulatory T cells and a reduction of TH2 cells.
61
Notably, here we are showing that this process may be supported
by shifts in the particular subpopulations of monocytes, namely,
an increase in the intermediate monocytes and decrease in the
nonclassical monocytes. In addition, we noted an AIT-induced in-
crease in the monocyte clusters with low HLA-DR expression.
High HLA-DR expression level is associated with monocyte acti-
vation and their proinflammatory function.62,63 Taken together,
therefore, the observed changes may be recognized as an AIT-
induced decrease in the activation of circulatingmonocytes. Inter-
estingly, monocytes with proinflammatory properties, which have
a nonclassical, activated phenotype (CD141CD1611) recruited
from the periphery, are crucial players in the promotion of
local inflammatory responses in individuals with allergy.64 In
contrast, intermediate monocytes were shown to possess anti-
inflammatory properties with significantly reduced expression
of proinflammatory TNF and IL-1b and high expression of anti-
inflammatory IL-10.31 Moreover, they have reduced capability
to present antigens to naive T cells in lymph nodes and thus
may serve as tolerogenic cells.65 Consequently, our current find-
ings that the AIT-induced shift toward the increase in intermediate
monocytes and decrease in nonclassical monocytes, together with
the decrease in HLA-DR1 clusters, may indicate the systemic
response to limit local inflammation and support locally induced
tolerance to allergens.
Notably, tolerogenic DCs represent a heterogeneous subset of
cells with immature or semimature phenotype that is highly
sensitive to local microenvironmental changes. After stimulation
with inflammatory mediators and antigens, the maturation pro-
cess is induced. It manifests itself in changes in both the
phenotype of DCs and the composition of different DC subsets.66
We have demonstrated that this process might be observed in the
pollen season in both allergy-free individuals and AIT-treated in-
dividuals with allergy. Notably, pDCs in their steady state express
low levels of HLA-DR and costimulatory molecules67 and induce
suboptimal T-cell priming, leading to T-cell anergy or tolerance.
They have been shown to induce regulatory T cells and mediate
oral tolerance.43,68 Furthermore, pDCs may exert a protective
role against type 2 inflammation.69,70 Therefore, the lower fre-
quency of circulating pDCs in individuals with allergy at baseline
may reflect their lower tolerogenic potential, which is further tar-
geted and efficiently restored by AITas a manifestation of trained
tolerance. Our findings are in line with previous observations
showing an increased frequency of pDCs after 1 year of AIT.71
In contrast to our current results, however, no changes in any
mDCs subsets after 8 weeks or 1 year of subcutaneous AIT
were observed.71 This might be due to the slightly different
time points and differences in the AIT schemes. It should be noted
that mDCs were shown to support TH2 responses in patients with
allergy and thus may promote allergic inflammation.72 Therefore,
the systemic reduction in the frequency of CD1c1 mDCs during
the course of AIT that was observed in this study may be associ-
ated with the previously reported reduction of TH2 cells.
In summary, here we have shown that AIT induces time-
dependent changes in the composition and phenotypes of circu-
lating ILCs, monocyte, and DC subpopulations. Our data demon-
strate an in vivo switch toward tolerance-inducing subsets with a
subsequent reduction of proinflammatory cells. It represents evi-
dence of an AIT-induced trained tolerance and underlines theneed for complex assessment of circulating innate immune cells,
which may open a new window for monitoring AIT responses.
Key messages
d ILC2s and ILC3s are downregulated and ILC1s are upre-
gulated during the course of AIT.
d The AIT-induced systemic decrease of ILC2s and increase
of ILC1s remains stable up to the third year of AIT.
d ILC1 clusters with higher CD25 expression are increased
during the course of AIT.
d AIT induces a shift from a proinflammatory (nonclas-
sical) toward an anti-inflammatory (intermediate) pheno-
type of circulating monocytes in the first year after AIT.
d pDCs and CD1411 mDCs are upregulated during the
course of AIT.
d AIT induces changes in the repertoire of systemic innate
immune cells, restoring their frequency and composition
toward a healthy immune status.
REFERENCES
1. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete
tolerance to allergens. Sci Transl Med 2015;7:280ps6.
2. Maeda K, Caldez MJ, Akira S. Innate immunity in allergy. Allergy 2019;74:1660-74.
3. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled al-
lergens and predictive biomarkers. J Allergy Clin Immunol 2017;140:1485-98.
4. Domınguez-Andres J, Joosten LA, Netea MG. Induction of innate immune mem-
ory: the role of cellular metabolism. Curr Opin Immunol 2019;56:10-6.
5. Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic target-
ing of trained immunity. Nat Rev Drug Discov 2019;18:553-66.
6. Netea MG, Domınguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E,
et al. Defining trained immunity and its role in health and disease. Nat Rev Immu-
nol 2020;20:375-88.
7. G1obinska A, Kowalski ML. Innate lymphoid cells: the role in respiratory infec-
tions and lung tissue damage. Expert Rev Clin Immunol 2017;13:991-9.
8. Bj€orklund A, Forkel M, Picelli S, Konya V, Theorell J, Friberg D, et al. The het-
erogeneity of human CD127(1) innate lymphoid cells revealed by single-cell RNA
sequencing. Nat Immunol 2016;17:451-60.
9. Li S, Morita H, Sokolowska M, Tan G, Boonpiyathad T, Opitz L, et al. Gene
expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells.
J Allergy Clin Immunol 2019;143:2321-5.
10. Nagasawa M, Heesters BA, Kradolfer CMA, Krabbendam L, Martinez-Gonzalez I,
de Bruijn MJW, et al. KLRG1 and NKp46 discriminate subpopulations of human
CD117. J Exp Med 2019;216:1762-76.
11. Stehle C, Hernandez DC, Romagnani C. Innate lymphoid cells in lung infection
and immunity. Immunol Rev 2018;286:102-19.
12. Castellanos JG, Longman RS. The balance of power: innate lymphoid cells in tis-
sue inflammation and repair. J Clin Invest 2019;129:2640-50.
13. Kortekaas Krohn I, Shikhagaie MM, Golebski K, Bernink JH, Breynaert C, Creyns
B, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: clinical
implications. Allergy 2018;73:837-50.
14. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic
inflammation. J Allergy Clin Immunol 2016;138:1253-64.
15. Winkler C, Hochd€orfer T, Israelsson E, Hasselberg A, Cavallin A, Th€orn K, et al.
Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic
patients. J Allergy Clin Immunol 2019;144:61-9.e7.
16. Kouser L, Kappen J, Walton RP, Shamji MH. Update on biomarkers to monitor
clinical efficacy response during and post treatment in allergen immunotherapy.
Curr Treat Options Allergy 2017;4:43-53.
17. Mitthamsiri W, Pradubpongsa P, Sangasapaviliya A, Boonpiyathad T. Decreased
CRTH2 expression and response to allergen re-stimulation on innate lymphoid
cells in patients with allergen-specific immunotherapy. Allergy Asthma Immunol
Res 2018;10:662-74.
18. Lombardi V, Beuraud C, Neukirch C, Moussu H, Morizur L, Horiot S, et al. Circu-
lating innate lymphoid cells are differentially regulated in allergic and nonallergic
subjects. J Allergy Clin Immunol 2016;138:305-8.
J ALLERGY CLIN IMMUNOL
VOLUME 147, NUMBER 5
ELJASZEWICZ ET AL 187719. Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal in-
creases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous
grass pollen immunotherapy. J Allergy Clin Immunol 2014;134:1193-5.e4.
20. Deniz G, van de Veen W, Akdis M. Natural killer cells in patients with allergic dis-
eases. J Allergy Clin Immunol 2013;132:527-35.
21. Gorska MM. Natural killer cells in asthma. Curr Opin Allergy Clin Immunol 2017;
17:50-4.
22. Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of
monocytes. Immunity 2018;49:595-613.
23. Lambrecht BN, Hammad H. Lung dendritic cells in respiratory viral infection and
asthma: from protection to immunopathology. Annu Rev Immunol 2012;30:243-70.
24. Lambrecht BN, Hammad H. Lung dendritic cells: targets for therapy in allergic dis-
ease. Handb Exp Pharmacol 2009;99-114.
25. Hasegawa H, Matsumoto T. Mechanisms of tolerance induction by dendritic cells.
Front Immunol 2018;9:350.
26. Kelly A, Gunaltay S, McEntee CP, Shuttleworth EE, Smedley C, Houston SA, et al.
Human monocytes and macrophages regulate immune tolerance via integrin avb8-
mediated TGFb activation. J Exp Med 2018;215:2725-36.
27. Hrusch CL, Tjota MY, Sperling AI. The role of dendritic cells and monocytes in the
maintenance and loss of respiratory tolerance. Curr Allergy Asthma Rep 2015;15:494.
28. Eguiluz-Gracia I, Bosco A, Dollner R, Melum GR, Lexberg MH, Jones AC, et al.
Rapid recruitment of CD14(1) monocytes in experimentally induced allergic
rhinitis in human subjects. J Allergy Clin Immunol 2016;137:1872-81.e12.
29. Eguiluz-Gracia I, Malmstrom K, Dheyauldeen SA, Lohi J, Sajantila A, Aalokken
R, et al. Monocytes accumulate in the airways of children with fatal asthma. Clin
Exp Allergy 2018;48:1631-9.
30. Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical mono-
cytes in health and disease. Annu Rev Immunol 2019;37:439-56.
31. Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszew-
ska I, et al. Collaborating with the enemy: function of macrophages in the devel-
opment of neoplastic disease. Mediators Inflamm 2013;2013:831387.
32. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomen-
clature of monocytes and dendritic cells in blood. Blood 2010;116:e74-80.
33. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli
M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Res 2014;74:
1287-93.
34. Ogle ME, Segar CE, Sridhar S, Botchwey EA. Monocytes and macrophages in tis-
sue repair: implications for immunoregenerative biomaterial design. Exp Biol Med
(Maywood) 2016;241:1084-97.
35. Tang-Huau TL, Segura E. Human in vivo-differentiated monocyte-derived den-
dritic cells. Semin Cell Dev Biol 2019;86:44-9.
36. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-
cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and
progenitors. Science 2017;356.
37. Jahnsen FL, Moloney ED, Hogan T, Upham JW, Burke CM, Holt PG. Rapid den-
dritic cell recruitment to the bronchial mucosa of patients with atopic asthma in
response to local allergen challenge. Thorax 2001;56:823-6.
38. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al.
The nature of the principal type 1 interferon-producing cells in human blood. Sci-
ence 1999;284:1835-7.
39. Young LJ, Wilson NS, Schnorrer P, Proietto A, ten Broeke T, Matsuki Y, et al.
Differential MHC class II synthesis and ubiquitination confers distinct antigen-
presenting properties on conventional and plasmacytoid dendritic cells. Nat Immu-
nol 2008;9:1244-52.
40. Global Initiative for Asthma. Global strategy for asthma management and preven-
tion, 2019. Available at: www.ginasthma.org. Accessed January 21, 2020.
41. Pfaar O, Bastl K, Berger U, Buters J, Calderon MA, Clot B, et al. Defining pollen
exposure times for clinical trials of allergen immunotherapy for pollen-induced rhi-
noconjunctivitis - an EAACI position paper. Allergy 2017;72:713-22.
42. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al.
Recommendations for the standardization of clinical outcomes used in allergen
immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position ppaper.
Allergy 2014;69:854-67.
43. Palomares O, Ruckert B, Jartti T, Kucuksezer UC, Puhakka T, Gomez E, et al. In-
duction and maintenance of allergen-specific FOXP31 Treg cells in human tonsils
as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012;129:
510-20.e1-9.
44. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, et al.
Epigenetic programming of monocyte-to-macrophage differentiation and trained
innate immunity. Science 2014;345:1251086.
45. Netea MG, van der Meer JW. Trained immunity: an ancient way of remembering.
Cell Host Microbe 2017;21:297-300.
46. Sato K, Uto T, Fukaya T, Takagi H. Regulatory dendritic cells. Curr Top Microbiol
Immunol 2017;410:47-71.47. Morita H, Kubo T, R€uckert B, Ravindran A, Soyka MB, Rinaldi AO, et al. Induc-
tion of human regulatory innate lymphoid cells from group 2 innate lymphoid cells
by retinoic acid. J Allergy Clin Immunol 2019;143:2190-201.e9.
48. Boonpiyathad T, van de Veen W, Wirz O, Sokolowska M, R€uckert B, Tan G, et al.
Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust
mite-specific immunotherapy. J Allergy Clin Immunol 2019;143:1077-86.e10.
49. Boonpiyathad T, Sokolowska M, Morita H, R€uckert B, Kast JI, Wawrzyniak M,
et al. Der p 1-specific regulatory T-cell response during house dust mite allergen
immunotherapy. Allergy 2019;74:976-85.
50. Bacher P, Scheffold A. The effect of regulatory T cells on tolerance to airborne al-
lergens and allergen immunotherapy. J Allergy Clin Immunol 2018;142:1697-709.
51. Ryan JF, Hovde R, Glanville J, Lyu SC, Ji X, Gupta S, et al. Successful immuno-
therapy induces previously unidentified allergen-specific CD41 T-cell subsets.
Proc Natl Acad Sci U S A 2016;113:E1286-95.
52. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune
tolerance to allergens. World Allergy Organ J 2015;8:17.
53. Helfrich S, Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in res-
piratory allergic inflammation. Front Immunol 2019;10:930.
54. Martinez-Gonzalez I, Math€a L, Steer CA, Ghaedi M, Poon GF, Takei F. Allergen-
experienced group 2 innate lymphoid cells acquire memory-like properties and
enhance allergic lung inflammation. Immunity 2016;45:198-208.
55. Doherty TA, Scott D,Walford HH, KhorramN, Lund S, BaumR, et al. Allergen chal-
lenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate
lymphoid cells that express CD84. J Allergy Clin Immunol 2014;133:1203-5.
56. Verma M, Michalec L, Sripada A, Dyjack N, Gorska M, Seibold M, et al. The mo-
lecular and epigenetic mechanisms of innate lymphoid cells (ILCs) memory and its
relevance for asthma. J Allergy Clin Immunol 2020;145:AB1.
57. Sciume G, Shih HY, Mikami Y, O’Shea JJ. Epigenomic views of innate lymphoid
cells. Front Immunol 2017;8:1579.
58. Li N, van Unen V, H€ollt T, Thompson A, van Bergen J, Pezzotti N, et al. Mass cy-
tometry reveals innate lymphoid cell differentiation pathways in the human fetal
intestine. J Exp Med 2018;215:1383-96.
59. Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L, et al. c-Kit-
positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-
mediated pathologies. Nat Immunol 2019;20:992-1003.
60. Hochd€orfer T, Winkler C, Pardali K, Mj€osberg J. Expression of c-Kit discriminates
between two functionally distinct subsets of human type 2 innate lymphoid cells.
Eur J Immunol 2019;49:884-93.
61. Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory
T cell induction in man. Front Immunol 2015;6:569.
62. Kanakoudi-Tsakalidou F, Debonera F, Drossou-Agakidou V, Sarafidis K, Tzimouli
V, Taparkou A, et al. Flow cytometric measurement of HLA-DR expression on
circulating monocytes in healthy and sick neonates using monocyte negative selec-
tion. Clin Exp Immunol 2001;123:402-7.
63. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B,
et al. The proinflammatory CD141CD161DR11 monocytes are a major source
of TNF. J Immunol 2002;168:3536-42.
64. Zas1ona Z, Przybranowski S, Wilke C, van Rooijen N, Teitz-Tennenbaum S, Oster-
holzer JJ, et al. Resident alveolar macrophages suppress, whereas recruited mono-
cytes promote, allergic lung inflammation in murine models of asthma. J Immunol
2014;193:4245-53.
65. Gomez-Olarte S, Bola~nos NI, Echeverry M, Rodrıguez AN, Cuellar A, Puerta CJ,
et al. Intermediate monocytes and cytokine production associated with severe
forms of Chagas disease. Front Immunol 2019;10:1671.
66. Hayashi Y, Ishii Y, Hata-Suzuki M, Arai R, Chibana K, Takemasa A, et al.
Comparative analysis of circulating dendritic cell subsets in patients with atopic
diseases and sarcoidosis. Respir Res 2013;14:29.
67. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid den-
dritic cell precursors. Annu Rev Immunol 2005;23:275-306.
68. Chinthrajah RS, Hernandez JD, Boyd SD, Galli SJ, Nadeau KC. Molecular and
cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol
2016;137:984-97.
69. de Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, et al. Essential
role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harm-
less inhaled antigen. J Exp Med 2004;200:89-98.
70. Kool M, van Nimwegen M, Willart MA, Muskens F, Boon L, Smit JJ, et al. An
anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflam-
mation. J Immunol 2009;183:1074-82.
71. Lundberg K, Rydnert F, Broos S, Andersson M, Greiff L, Lindstedt M. Allergen-
specific immunotherapy alters the frequency, as well as the FcR and CLR expres-
sion profiles of human dendritic cell subsets. PLoS One 2016;11:e0148838.
72. Shen C, Hupin C, Froidure A, Detry B, Pilette C. Impaired ICOSL in human
myeloid dendritic cells promotes Th2 responses in patients with allergic rhinitis
and asthma. Clin Exp Allergy 2014;44:831-41.
